Antiangiogenic drugs and advanced proliferative diabetic retinopathy
| Autor: | Jefferson Augusto Santana Ribeiro, Andre Messias, Rodrigo Jorge |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Vascular Endothelial Growth Factor A
Pars plana medicine.medical_specialty Bevacizumab medicine.medical_treatment Angiogenesis Inhibitors Vitrectomy Anti-angiogenic drugs Antibodies Monoclonal Humanized chemistry.chemical_compound lcsh:Ophthalmology Diabetic retinopathy Ophthalmology medicine Humans Surgical treatment Vitreous hemorrhage Hemorragia vítrea Diabetic Retinopathy business.industry Retinopatia diabética General Medicine medicine.disease eye diseases Vascular endothelial growth factor medicine.anatomical_structure Inibidores da angiogênese chemistry lcsh:RE1-994 Retinal detachment Monoclonal sense organs business Descolamento retiniano medicine.drug Vitrectomia |
| Zdroj: | Arquivos Brasileiros de Oftalmologia, Vol 74, Iss 2, Pp 143-146 (2011) Arquivos Brasileiros de Oftalmologia v.74 n.2 2011 Arquivos brasileiros de oftalmologia Conselho Brasileiro de Oftalmologia (CBO) instacron:CBO |
| ISSN: | 1678-2925 |
| Popis: | Advanced diabetic retinopathy with tractional retinal detachment or persistent vitreous hemorrhage often requires surgical treatment with pars plana vitrectomy. Despite advances in vitrectomy, surgery for complications of diabetic retinopathy can be a challenge and may be impaired by intense fibrovascular proliferation. Antiangiogenic drugs have been used for the treatment of diabetic retinopathy because of their inhibitory action on vascular endothelial growth factor. In this review, we discuss aspects related to the adjuvant use of these drugs in vitrectomy for complications of diabetic retinopathy. Bevacizumab shows beneficial effects regarding the surgical technique facilitation, but its long-term benefit still needs to be studied. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|